ALK and adenocarcinoma: We reviewed the literatures and summarized the relevant clinicopathological and molecular characteristics of ALK/EGFR dual-positive cases; majority of cases were adenocarcinomas in the advanced stage and mainly involved Asian patients, most EGFR mutations were deletions in exon 19 and point mutations in exon 21, and patients showed differential sensitivities to EGFR-TKI and/or ALK-TKI13, 14, 16, 17.